Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation

Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases

DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452

The Statistical Analysis of Failure Time Data.

Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875

Validation of a combined comorbidity index

Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587

International scoring system for evaluating prognosis in myelodysplastic syndromes

Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427

Regression modelling strategies for improved prognostic prediction

Harrell, F. E., Lee, K. L., Califf, R. M., Pryor, D. B., & Rosati, R. A. (1984) · Statistics in Medicine · doi:10.1002/sim.4780030207 · Cited by 1,804

Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives

Romano, P. S., Roos, L. L., & Jollis, J. G. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90103-8 · Cited by 1,717

The pre-therapeutic classification of co-morbidity in chronic disease

Feinstein, A. R. (1970) · Journal of Chronic Diseases · doi:10.1016/0021-9681(70)90054-8 · Cited by 1,544

Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia

Storb, R. F., Deeg, H. J., Whitehead, J., Appelbaum, F. R., Beatty, P. G., Bensinger, W., Buckner, C. D., Clift, R. A., Doney, K., Farewell, V. T., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603203141201 · Cited by 1,411

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

McSweeney, P. A., Niederwieser, D. W., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., Maloney, D. G., Chauncey, T. R., Gooley, T. A., Hegenbart, U., Nash, R. A., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3390 · Cited by 1,386

Management of Hodgkin Lymphoma in Relapse after Autologous Stem Cell Transplant

Crump, M. (2008) · Hematology · doi:10.1182/asheducation-2008.1.326 · Cited by 67

Comorbidities and Hematopoietic Cell Transplantation Outcomes

Sorror, M. L. (2010) · Hematology · doi:10.1182/asheducation-2010.1.237 · Cited by 67

Critically ill allogenic HSCT patients in the intensive care unit: a systematic review and meta-analysis of prognostic factors of mortality

(GRRR-OH), O. B. T. G. D. R. E. R. R. D. P. D.-H., Saillard, C., Darmon, M., Bisbal, M., Sannini, A., Chow‐Chine, L., Faucher, M., Lengliné, É., Vey, N., Blaise, D., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0181-x · Cited by 67

90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma

Gopal, A. K., Guthrie, K. A., Rajendran, J. G., Pagel, J. M., Oliveira, G. L. D. S., Maloney, D. G., Matesan, M. C., Storb, R. F., & Press, O. W. (2011) · Blood · doi:10.1182/blood-2010-12-324392 · Cited by 66

Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide

Im, A., Rashidi, A., Wang, T., Hemmer, M., MacMillan, M. L., Pidala, J., Jagasia, M., Pavletic, S. Z., Majhail, N. S., Weisdorf, D. J., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.05.001 · Cited by 66

Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease

Farag, S. S., Zaid, M. I. A., Schwartz, J. E., Thakrar, T. C., Blakley, A. J., Abonour, R., Robertson, M. J., Broxmeyer, H. E., & Zhang, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2027372 · Cited by 66

Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML

Min, G. J., Cho, B., Park, S., Park, S., Jeon, Y., Shin, S., Yahng, S., Yoon, J., Lee, S.-E., Eom, K., et al. (2022) · Blood · doi:10.1182/blood.2021013671 · Cited by 66

Predictors of anxiety and depression in hematopoietic stem cell transplant patients during protective isolation

Tecchio, C., Bonetto, C., Bertani, M., Cristofalo, D., Lasalvia, A., Nichele, I., Bonani, A., Andreini, A., Benedetti, F. M., Ruggeri, M., et al. (2012) · Psycho-Oncology · doi:10.1002/pon.3215 · Cited by 72

Donor Chimerism Early after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival

Koreth, J., Kim, H. T., Nikiforow, S., Milford, E. L., Armand, P. A., Cutler, C. S., Glotzbecker, B. E., Ho, V. T., Antin, J. H., Soiffer, R. J., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.05.025 · Cited by 66

High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission

Schmid, C., Schleuning, M., Hentrich, M., Markl, G. E., Gerbitz, A., Tischer, J., Ledderose, G., Oruzio, D. V., Hiddemann, W., & Kolb, H.-J. (2008) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705965 · Cited by 66

Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia

Ossenkoppele, G. J., Janssen, J. J. W. M., & van de Loosdrecht, A. A. (2015) · Haematologica · doi:10.3324/haematol.2015.139105 · Cited by 66

Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long‐term outcomes of a prospective randomized trial

Chang, Y., Wang, Y., Mo, X., Zhang, X., Xu, L., Yan, C., Chen, H., Chen, Y., Chen, Y., Han, W., et al. (2017) · Cancer · doi:10.1002/cncr.30540 · Cited by 66

Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation

Kong, Y., Wang, Y., Zhang, Y., Shi, M.-M., Mo, X., Sun, Y., Chang, Y., Xu, L., Zhang, X., Liu, K., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018029454 · Cited by 67

A Novel Reduced-Intensity Conditioning Regimen Induces a High Incidence of Sustained Donor-Derived Neutrophil and Platelet Engraftment after Double-Unit Cord Blood Transplantation

Ponce, D. M., Sauter, C. S., Devlin, S. M., Lubin, M. N., Gonzales, A. M., Kernan, N. A., Scaradavou, A., Giralt, S. A., Goldberg, J. D., Koehne, G., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.02.007 · Cited by 65

Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness

Palmieri, R., Paterno, G., Bellis, E. D., Mercante, L., Buzzatti, E., Esposito, F., Principe, M. I. D., Maurillo, L., Buccisano, F., & Venditti, A. (2020) · Cancers · doi:10.3390/cancers12010120 · Cited by 66

Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era

Yeh, J. C., Whited, L. K., Saliba, R. M., Rondón, G., Banchs, J. A., Shpall, E. J., Champlin, R. E., & Popat, U. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004846 · Cited by 65

Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission

Martino, R., Valcárcel, D., Brunet, S., Sureda, A. M., & Sierra, J. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705879 · Cited by 65

Body mass index and bioelectrical impedance phase angle as potentially modifiable nutritional markers are independent risk factors for outcome in allogeneic hematopoietic cell transplantation

Urbain, P., Birlinger, J. A., Ihorst, G., Biesalski, H. K., Finke, J., & Bertz, H. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1573-4 · Cited by 65

Impact of graft sources on immune reconstitution and survival outcomes following allogeneic stem cell transplantation

Ando, T., Tachibana, T., Tanaka, M., Suzuki, T., Ishiyama, Y., Koyama, S., Ogusa, E., Numata, A., Matsumoto, K., Kanamori, H., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001021 · Cited by 66

Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT

DeFilipp, Z. M., Duarte, R. F., Snowden, J. A., Majhail, N. S., Greenfield, D., López‐Miranda, J., Arat, M., Baker, K. S., Burns, L. J., Duncan, C., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.05.007 · Cited by 64

Impact of donor age and kinship on clinical outcomes after T-cell–replete haploidentical transplantation with PT-Cy

Mariotti, J., Raiola, A. M., Evangelista, A., Carella, A. M., Martino, M. V., Patriarca, F. F., Risitano, A. M., Bramanti, S., Busca, A., Giaccone, L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001620 · Cited by 65

Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT

Heidenreich, S., Ziagkos, D., de Wreede, L. C., van Biezen, A., Finke, J., Platzbecker, U., Niederwieser, D. W., Einsele, H., Bethge, W. A., Schleuning, M., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.09.027 · Cited by 64

Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy

Arai, Y., Takeda, J., Aoki, K., Kondo, T., Takahashi, S., Onishi, Y., Ozawa, Y., Aotsuka, N., Kouzai, Y., Nakamae, H., et al. (2015) · Blood · doi:10.1182/blood-2015-04-642652 · Cited by 64

Application of Global Lung Function Initiative Global Spirometry Reference Equations across a Large, Multicenter Pulmonary Function Lab Population

Kanj, A., Scanlon, P. D., Yadav, H., Smith, W. T., Herzog, T. L., Bungum, A. O., Poliszuk, D., Fick, E., Lee, A. S., & Niven, A. S. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202303-0613oc · Cited by 65

Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications

On behalf of the IRON-2 Study Group, Remacha, A. F., Arrizabalaga, B., Villegas, A., Durán, M. S., Hermosín, L., de Paz, R., García, M., Díez‐Campelo, M., & Sanz, G. F. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2274-y · Cited by 63

Impact of Donor Age on Outcome after Allogeneic Hematopoietic Cell Transplantation

Rezvani, A. R., Storer, B. E., Guthrie, K. A., Schoch, H. G., Maloney, D. G., Sandmaier, B. M., & Storb, R. F. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.09.021 · Cited by 67

Possible Association between Obesity and Posttransplantation Complications Including Infectious Diseases and Acute Graft-versus-Host Disease

Fuji, S., Kim, S.-W., Yoshimura, K.-I., Akiyama, H., Okamoto, S.-I., Sao, H., Takita, J., Kobayashi, N., & Mori, S. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.10.029 · Cited by 63

Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes

Bannow, B. S., Salit, R. B., Storer, B. E., Stevens, E. A., Wu, D., Yeung, C. C. S., Fang, M., Petersdorf, E. W., Linenberger, M. L., Woo, J., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.09.016 · Cited by 64

The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases

Thakar, M. S., Broglie, L. A., Logan, B. R., Artz, A. S., Bunin, N., Burroughs, L. M., Fretham, C., Jacobsohn, D. A., Loren, A. W., Kurtzberg, J., et al. (2018) · Blood · doi:10.1182/blood-2018-09-876284 · Cited by 63

Improvement of early mortality in single‐unit cord blood transplantation for Japanese adults from 1998 to 2017

Konuma, T., Kanda, J., Inamoto, Y., Hayashi, H., Kobayashi, S., Uchida, N., Sugio, Y., Tanaka, M., Kobayashi, H., Kouzai, Y., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25705 · Cited by 63

Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis

Kittai, A. S., Huang, Y., Gordon, M. J., Denlinger, N., Mian, A., Fitzgerald, L. A., Bishop, J., Nagle, S. J., Stephens, D. M., Jaglowski, S. M., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.09.028 · Cited by 62

Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy

Saito, A. M., Zahrieh, D., Cutler, C. S., Ho, V. T., Antin, J. H., Soiffer, R. J., Alyea, E. P., & Lee, S. J. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705733 · Cited by 62

Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Older Adults: Geriatric Principles in the Transplant Clinic

Wildes, T. M., Stirewalt, D. L., Medeiros, B. C., & Hurria, A. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0010 · Cited by 62

Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group

Pleyer, L., Stauder, R., Burgstaller, S., Schreder, M., Tinchon, C., Pfeilstöcker, M., Steinkirchner, S., Melchardt, T., Mitrovic, M., Girschikofsky, M., et al. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-32 · Cited by 61

Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant

Malki, M. M. A., Tsai, N., Palmer, J. M., Mokhtari, S., Tsai, W., Cao, T. M., Ali, H., Salhotra, A., Arslan, S., Aldoss, I. T., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004192 · Cited by 60

Change in Patients’ Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma

Barata, A., Hoogland, A. I., Kommalapati, A., Logue, J., Welniak, T. L., Hyland, K. A., Eisel, S. L., Small, B. J., Jayani, R., Booth‐Jones, M., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.05.015 · Cited by 61

A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation

Armand, P. A., Kim, H. T., Cutler, C. S., Ho, V. T., Koreth, J., Ritz, J., Alyea, E. P., Antin, J. H., & Soiffer, R. J. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.07.016 · Cited by 61

Impact of Acute Kidney Injury on Long-Term Mortality after Nonmyeloablative Hematopoietic Cell Transplantation

Parikh, C. R., Yarlagadda, S. G., Storer, B. E., Sorror, M. L., Storb, R. F., & Sandmaier, B. M. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.12.492 · Cited by 61

Complex karyotype predicts for inferior outcomes following reduced‐intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia

Jaglowski, S. M., Ruppert, A. S., Heerema, N. A., Bingman, A. K., Flynn, J. M., Grever, M. R., Jones, J. A., Elder, P., Devine, S. M., Byrd, J. C., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09239.x · Cited by 61

Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia

Üstün, C., Courville, E. L., DeFor, T. E., Dolan, M., Randall, N. M., Yohe, S. L., Bejanyan, N., Warlick, E. D., Brunstein, C. G., Weisdorf, D. J., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.10.024 · Cited by 61

Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome

Atallah, E. L., Logan, B. R., Chen, M., Cutler, C. S., Deeg, J., Jacoby, M. A., Champlin, R. E., Nishihori, T., Confer, D. L., Gajewski, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5140 · Cited by 61

Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome

Kim, H. T., Armand, P. A., Frederick, D., Andler, E., Cutler, C. S., Koreth, J., Alyea, E. P., Antin, J. H., Soiffer, R. J., Ritz, J., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.01.019 · Cited by 60

Lung Histology Predicts Outcome of Bronchiolitis Obliterans Syndrome after Hematopoietic Stem Cell Transplantation

Holbro, A., Lehmann, T., Girsberger, S., Stern, M., Gambazzi, F., Lardinois, D., Heim, D. A., Passweg, J. R., Tichelli, A., Bubendorf, L., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.03.017 · Cited by 60

Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma

Weiss, L., Melchardt, T., Habringer, S., Boekstegers, A., Hufnagl, C., Neureiter, D., Hopfinger, G., Greil, R., & Egle, A. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt481 · Cited by 60

Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease

El-Jawahri, A. R., Pidala, J., Inamoto, Y., Chai, X., Khera, N., Wood, W. A., Cutler, C. S., Arora, M., Carpenter, P. A., Palmer, J. M., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.05.001 · Cited by 60

Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation

Shouval, R., Kouniavski, E., Fein, J. A., Danylesko, I., Shem‐Tov, N., Geva, M., Yerushalmi, R., Shimoni, A., & Nagler, A. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13299 · Cited by 59

Impact of comorbidity indexes on non-relapse mortality

Xhaard, A., Porcher, R., Chien, J. W., de Latour, R. P., Robin, M., Ribaud, P., Rocha, V., Devergié, A., Ferry, C., Martin, P. J., et al. (2008) · Leukemia · doi:10.1038/leu.2008.197 · Cited by 60

Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: A comparative clinical analysis

Flynn, C. M., Hirsch, B. A., DeFor, T. E., Barker, J. N., Miller, J. S., Wagner, J. E., Blazar, B. R., Burns, L. J., MacMillan, M. L., Arora, M., et al. (2007) · American Journal of Hematology · doi:10.1002/ajh.20989 · Cited by 60

The European Blood and Marrow Transplantation Textbook for Nurses

Kenyon, M., & Babić, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-50026-3 · Cited by 68

Risk factors for vancomycin-resistant enterococcus bacteremia and its influence on survival after allogeneic hematopoietic cell transplantation

Tavadze, M., Rybicki, L. A., Mossad, S. B., Avery, R. K., Yurch, M. A., Pohlman, B. L., Duong, H., Dean, R. M., Hill, B., Andresen, S., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.150 · Cited by 59

High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: A Nationwide Retrospective Study

Chihara, D., Izutsu, K., Kondo, E., Sakai, R., Mizuta, S., Yokoyama, K., Kaneko, H., Kato, K., Hasegawa, Y., Chou, T., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.01.025 · Cited by 59

Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and −5/5q−

Middeke, J. M., Beelen, D. W., Stadler, M., Göhring, G., Schlegelberger, B., Baurmann, H., Bug, G., Bellos, F., Mohr, B., Buchholz, S., et al. (2012) · Blood · doi:10.1182/blood-2012-03-417972 · Cited by 59

Centralized patient‐reported outcome data collection in transplantation is feasible and clinically meaningful

Shaw, B. E., Brazauskas, R., Millard, H. R., Fonstad, R. K., Flynn, K. E., Abernethy, A. P., Vogel, J., Petroske, C., Mattila, D., Drexler, R. J., et al. (2017) · Cancer · doi:10.1002/cncr.30936 · Cited by 58

Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study

Yang, J., Jiang, J., Cai, Y., Su, L., Wan, L., Zhu, J., Liu, H., Shao, S., Bai, H., Wang, C., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0382-3 · Cited by 59

Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma

Chen, R., Palmer, J. M., Tsai, N., Thomas, S. H., Siddiqi, T., Popplewell, L. L., Farol, L., Nademanee, A. P., & Forman, S. J. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.06.037 · Cited by 58

Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations

Greco, R., Ruggeri, A., McLornan, D. P., Snowden, J. A., Alexander, T., Angelucci, E., Averbuch, D., Bazarbachi, A. A., Hazenberg, M. D., Kałwak, K., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02701-3 · Cited by 69

Acute Myeloid Leukemia in the Elderly

Dombret, H., Raffoux, E., & Gardin, C. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.013 · Cited by 58

Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase

Pavlů, J., Kew, A. K., Taylor-Roberts, B., Auner, H. W., Marín, D., Olavarría, E., Kanfer, E., Macdonald, D. H. C., Milojković, D., Rahemtulla, A., et al. (2010) · Blood · doi:10.1182/blood-2010-01-263624 · Cited by 58

Older Age But Not Donor Health Impairs Allogeneic Granulocyte Colony-Stimulating Factor (G-CSF) Peripheral Blood Stem Cell Mobilization

Richa, E. M., Papari, M., Allen, J., Martinez, G., Wickrema, A., Anastasi, J., van Besien, K., & Artz, A. S. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.07.005 · Cited by 57

The Treatment of Elderly Patients With Acute Myeloid Leukemia

Krug, U. O., Büchner, T., Berdel, W. E., & Müller‐Tidow, C. (2011) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2011.0863 · Cited by 58

Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation

Heuser, M., Gabdoulline, R. R., Löffeld, P., Dobbernack, V., Kreimeyer, H., Pankratz, M., Flintrop, M., Liebich, A., Klesse, S., Panagiota, V., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3027-5 · Cited by 58

Worldwide study of hematopoietic allogeneic stem cell transplantation in pyruvate kinase deficiency

van Straaten, S., Bierings, M., Bianchi, P. I., Akiyoshi, K., Kanno, H., Badell, I., Chen, J., Huang, X., van Beers, E. J., Ekwattanakit, S., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.177857 · Cited by 58

Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies

Lin, R. J., Elko, T. A., Devlin, S. M., Shahrokni, A., Jakubowski, A. A., Dahi, P. B., Perales, M., Tamari, R., Shaffer, B. C., Sauter, C. S., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0654-6 · Cited by 57

Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation

Mo, X., Zhang, X., Xu, L., Wang, Y., Yan, C., Chen, H., Chen, Y., Han, W., Wang, F., Wang, J., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.06.014 · Cited by 57

Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study

Galloway-Peña, J., Peterson, C. B., Malik, F., Sahasrabhojane, P. V., Shah, D. P., Brumlow, C., Carlin, L. G., Chemaly, R. F., Im, J. S., Rondón, G., et al. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz173 · Cited by 57

Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients

Mushtaq, M. U., Shahzad, M., Chaudhary, S. G., Luder, M., Ahmed, N., Abdelhakim, H., Bansal, R., Balusu, R., DeJarnette, S., Divine, C. L., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.07.005 · Cited by 56

The role of hypomethylating agents in the treatment of elderly patients with AML

Al‐Ali, H. K., Jaekel, N., & Niederwieser, D. W. (2013) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2013.08.004 · Cited by 58

Choosing between stem cell therapy and drugs in myelofibrosis

Kröger, N. M., & Mesa, R. A. (2008) · Leukemia · doi:10.1038/sj.leu.2405080 · Cited by 57

High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation

Long-Boyle, J. R., Green, K., Brunstein, C. G., Cao, Q., Rogosheske, J., Weisdorf, D. J., Miller, J. S., Wagner, J. E., McGlave, P. B., & Jacobson, P. A. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.53 · Cited by 57

Maximally Tolerated Busulfan Systemic Exposure in Combination with Fludarabine as Conditioning before Allogeneic Hematopoietic Cell Transplantation

Perkins, J. B., Kim, J., Anasetti, C., Fernandez, H. F., Perez, L. E., Ayala, E., Kharfan‐Dabaja, M. A., Tomblyn, M. R., Sullivan, D. M., Pidala, J. A., et al. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.12.584 · Cited by 57

Effect of Hospital Volume on Clinical Outcome in Patients With Acute Pancreatitis, Based on a National Administrative Database

Murata, A., Matsuda, S., Mayumi, T., Yokoe, M., Kuwabara, K., Ichimiya, Y., Fujino, Y., Kubo, T., Fujimori, K., & Horiguchi, H. (2011) · Pancreas · doi:10.1097/mpa.0b013e31821bd233 · Cited by 57

Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT)

Jantunen, E., Canals, C., Attal, M., Thomson, K. J., Milpied, N. J., Buzyn, A., Ferrant, A., Biron, P., Crawley, C. R., Schattenberg, A. V. M. B., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr035 · Cited by 57

Relapsed Hodgkin Lymphoma in Older Patients: A Comprehensive Analysis From the German Hodgkin Study Group

Böll, B., Goergen, H., Arndt, N., Meißner, J., Krause, S. W., Schnell, R., von Tresckow, B., Eichenauer, D. A., Sasse, S., Fuchs, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.8246 · Cited by 57

Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia

Aoki, J., Kanamori, H., Tanaka, M., Yamasaki, S., Fukuda, T., Ogawa, H., Iwato, K., Ohashi, K., Okumura, H., Onizuka, M., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.24270 · Cited by 57

Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older

Konuma, T., Tsukada, N., Kanda, J., Uchida, N., Ohno, Y., Miyakoshi, S., Kanamori, H., Hidaka, M., Sakura, T., Onizuka, M., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24340 · Cited by 57

Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study

Voso, M. T., Leone, G. G. M., Piciocchi, A., Fianchi, L., Santarone, S., Candoni, A., Criscuolo, M., Masciulli, A., Cerqui, E., Molteni, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx154 · Cited by 57

Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation

Doki, N., Suyama, M., Sasajima, S., Ota, J., Igarashi, A., Mimura, I., Morita, H., Fujioka, Y., Sugiyama, D., Nishikawa, H., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3069-8 · Cited by 57

Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors

Montoro, J., Piñana, J. L., Hernández‐Boluda, J. C., Hernani, R., Lorenzo, I., Pérez, A., Guerreiro, M., Balaguer‐Roselló, A., Sanz, G. F., Carretero, C., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0921-6 · Cited by 56

Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines

DeFilipp, Z. M., Ciurea, S. O., Cutler, C. S., Robin, M., Warlick, E. D., Nakamura, R., Brunner, A. M., Dholaria, B., Walker, A. R., Kröger, N. M., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.11.014 · Cited by 57

Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors

Majhail, N. S., Brunstein, C. G., Shanley, R., Sandhu, K., McClune, B. L., Oran, B., Warlick, E. D., Wagner, J. E., & Weisdorf, D. J. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.114 · Cited by 56

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation

Oran, B., Wagner, J. E., DeFor, T. E., Weisdorf, D. J., & Brunstein, C. G. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.01.007 · Cited by 56

A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low‐, intermediate‐, and high‐risk groups: reactivation risk is increased by graft‐versus‐host disease only in the intermediate‐risk group

George, B., Kerridge, I., Gilroy, N. M., Huang, G., Hertzberg, M., Bradstock, K. F., & Gottlieb, D. J. (2012) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2011.00706.x · Cited by 56

Favorable Outcomes in Elderly Patients Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma

Dahi, P. B., Tamari, R., Devlin, S. M., Maloy, M., Bhatt, V., Scordo, M., Goldberg, J., Zelenetz, A. D., Hamlin, P. A., Matasar, M. J., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.08.019 · Cited by 56

Hematopoietic Cell Transplantation–Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation

Berro, M., Arbelbide, J. A., Rivas, M. M., Basquiera, A. L., Ferini, G. A., Vitriu, A. V., Foncuberta, C., Escobar, N. F., Requejo, A., Milovic, V., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.06.014 · Cited by 56

Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study

van Bijnen, S., de Vries‐Bouwstra, J., van den Ende, C. H. M., Boonstra, M., Kroft, L. J. M. L., Geurts, B. H. J., Snoeren, M. M., Schouffoer, A. A., Spierings, J., van Laar, J. M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217058 · Cited by 56

Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)

Klepin, H. D., Ritchie, E. K., Major-Elechi, B. T., Le‐Rademacher, J. G., Seisler, D. K., Storrick, L., Sanford, B. L., Marcucci, G., Zhao, W., Geyer, S. A., et al. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.10.002 · Cited by 55

Myelodysplastic Syndromes: Diagnosis and Staging

Malcovati, L., & Nimer, S. D. (2008) · Cancer Control · doi:10.1177/107327480801504s02 · Cited by 55

Similar and Promising Outcomes in Lymphoma Patients Treated with Myeloablative or Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation

Tomblyn, M., Brunstein, C. G., Burns, L. J., Miller, J. S., MacMillan, M. L., DeFor, T. E., & Weisdorf, D. J. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.02.014 · Cited by 55

Hematopoietic stem cell transplantation: a review and recommendations for follow-up care for the general practitioner

Passweg, J. R., Halter, J. P., Bucher, C., Gerull, S., Heim, D. A., Rovó, A., Buser, A. S., Stern, M., & Tichelli, A. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13696 · Cited by 61

Prognostic Importance of Pretransplant Functional Capacity After Allogeneic Hematopoietic Cell Transplantation

Jones, L. W., Devlin, S. M., Maloy, M., Wood, W. A., Tuohy, S., Espiritu, N. G., Aquino, J., Kendig, T., Michalski, M., Gyurkocza, B., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0200 · Cited by 56

Utility of Comorbidity Assessment in Predicting Transplantation-Related Toxicity Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Labonté, L. E., Iqbal, T. H., Zaidi, M. A., McDiarmid, S. A., Huebsch, L. B., Tay, J., Atkins, H. L., & Allan, D. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.06.019 · Cited by 54

Outcomes of alemtuzumab‐based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes

Lim, Z. Y., Ho, A. Y. L., Ingram, W. A., Kenyon, M., Pearce, L., Czepulkowski, B. H., Devereux, S., Duarte, R. F., Pagliuca, A., & Mufti, G. J. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06272.x · Cited by 55

Peripheral Blood Grafts for T Cell–Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome

Raj, R. V., Hamadani, M., Szabó, A., Pasquini, M. C., Shah, N. N., Drobyski, W. R., Shaw, B. E., Saber, W., Rizzo, J. D., Jerkins, J. H., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.04.010 · Cited by 55

MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT

Andrlová, H., Miltiadous, O., Kousa, A. I., Dai, A., DeWolf, S., Violante, S. N., Park, H.-Y., Janaki‐Raman, S., Gardner, R., Daker, S. E., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj2829 · Cited by 56

Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60–78 years of age

Samuelson, S. J., Sandmaier, B. M., Heslop, H. E., Popat, U., Carrum, G., Champlin, R. E., Storb, R. F., Prchal, J. T., Gooley, T. A., & Deeg, H. J. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08582.x · Cited by 54

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

Vyas, P., Appelbaum, F. R., & Craddock, C. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.10.026 · Cited by 54

Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies

Magenau, J. M., Tobai, H., Pawarode, A., Braun, T. W., Peres, E. M., Reddy, P. R., Kitko, C. L., Choi, S. W., Yanik, G. A., Frame, D. G., et al. (2011) · Blood · doi:10.1182/blood-2011-06-358010 · Cited by 54

What Is the Role for Donor Natural Killer Cells after Nonmyeloablative Conditioning?

Baron, F., Petersdorf, E. W., Gooley, T. A., Sandmaier, B. M., Malkki, M., Chauncey, T. R., Maloney, D. G., & Storb, R. F. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.01.018 · Cited by 54

Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission

Baron, F., & Storb, R. F. (2007) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3280168462 · Cited by 54

Outcome of therapy-related myeloid neoplasms treated with azacitidine

Fianchi, L., Criscuolo, M., Lunghi, M., Gaïdano, G., Breccia, M., Levis, A., Finelli, C., Santini, V., Musto, P., Olíva, E. N., et al. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-44 · Cited by 54

TRANSPLANTATION Hematopoietic cell transplantation (HCT)–specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Sorror, M. L., Maris, M. B., Storb, R. F., Baron, F., S, B. M., Maloney, D. G., & Storer, B. E. (2016)

Assignment of scores for the hematopoietic cell transplantation comorbidity index: integer vs exact weights

Sorror, M. L., Storer, B. E., & Storb, R. F. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.131 · Cited by 9

54: Hematopoietic cell transplantation-comorbidity index (HCT-CI)

Kassar, M., Shell, K., Gregory, S. A., Venugopal, P., Shammo, J. M., & Fung, H. C. H. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2006.12.057

Hematopoietic Cell Transplantation-Specific Comorbidity Index To Predict Non-Relapse Mortality and Survival after Allografting.

Kato, R., Fukuda, T., Usui, E., Yamasaki, S., Maruyama, D., Morita, Y., Kim, S., Mori, S., Tanosaki, R., Tajima, K., et al. (2005) · Blood · doi:10.1182/blood.v106.11.2731.2731 · Cited by 1

Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study

Sorror, M. L., Logan, B. R., Zhu, X., Rizzo, J. D., Cooke, K. R., McCarthy, P. L., Ho, V. T., Horowitz, M. M., & Pasquini, M. C. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.04.004 · Cited by 222